Skip to main content

Articles

Page 1 of 2

  1. Various breast cancer (BC) treatments, such as chemotherapy and targeted therapies, increase cardiotoxicity-risk and lead to premature ischemic heart disease and heart failure among survivors. Reducing this ad...

    Authors: Yvonne Koop, Saloua El Messaoudi, Hester Vermeulen, Angela H. E. M. Maas and Femke Atsma

    Citation: Cardio-Oncology 2020 6:14

    Content type: Research

    Published on:

  2. Adverse cardiac remodeling is an important precursor to anthracycline-related cardiac dysfunction, however conventional remodeling indices are limited. We sought to examine the utility of statistical atlas-der...

    Authors: Hari K. Narayan, Ronghui Xu, Nickolas Forsch, Sachin Govil, David Iukuridze, Lanie Lindenfeld, Eric Adler, Sanjeet Hegde, Adriana Tremoulet, Bonnie Ky, Saro Armenian, Jeffrey Omens and Andrew D. McCulloch

    Citation: Cardio-Oncology 2020 6:13

    Content type: Research

    Published on:

  3. Radiation-induced coronary artery disease (R-CAD) has become an increasingly recognized phenomenon. Although the clinical relationship between radiation therapy and CAD risk is well known, there is minimal inv...

    Authors: Yaser Khalid, Michael Fradley, Neethi Dasu, Kirti Dasu, Ankit Shah and Adam Levine

    Citation: Cardio-Oncology 2020 6:12

    Content type: Research

    Published on:

  4. Doxorubicin remains one of the most common causes of cardiotoxicity in patients with lymphoma, leading to significant morbidity and mortality. Early decline in left ventricular (LV) ejection fraction predicts ...

    Authors: Maria Isabel Camara Planek, Ahmad Manshad, Kyaw Hein, Mohamad Hemu, Fatima Ballout, Rajiv Varandani, Parameswaran Venugopal and Tochukwu Okwuosa

    Citation: Cardio-Oncology 2020 6:10

    Content type: Research

    Published on:

  5. Cardio-Oncology (CO) is a new subspecialty that thrives mostly in large academic quaternary centers. This study describes how to establish a successful cardio-oncology program, with limited resources, in order...

    Authors: Diego Sadler, Chakra Chaulagain, Beatrice Alvarado, Robert Cubeddu, Elizabeth Stone, Thomas Samuel, Bruno Bastos, David Grossman, Chieh-Lin Fu, Evan Alley, Arun Nagarajan, Timmy Nguyen, Wesam Ahmed, Leah Elson and Zeina Nahleh

    Citation: Cardio-Oncology 2020 6:9

    Content type: Research

    Published on:

  6. Cancer survivors with prior chest radiation therapy (C-XRT) frequently present with aortic stenosis (AS) as the first manifestation of radiation-induced heart disease. They are considered high-risk for surgica...

    Authors: Meer Rabeel Zafar, Syed Farrukh Mustafa, Timothy W. Miller, Talal Alkhawlani and Umesh C. Sharma

    Citation: Cardio-Oncology 2020 6:8

    Content type: Research

    Published on:

  7. Contrasting to the well documented tyrosine kinase inhibitor (TKI)-induced hypertension, little is known on their intrinsic vasomotor effects. We investigated the vasomotor effects of sorafenib, a widely used ...

    Authors: Hubert Dabiré, Fatou Dramé, Nelly Cita and Bijan Ghaleh

    Citation: Cardio-Oncology 2020 6:7

    Content type: Research

    Published on:

  8. Radiotherapy has been associated with late dose-dependent cardiovascular toxicity. In this cross-sectional pilot study, radiation dose distributions were correlated with areas of localized and diffuse myocardi...

    Authors: Anthony Ricco, Alexander Slade, Justin M. Canada, John Grizzard, Franklin Dana, Leila Rezai Gharai, Keith Neiderer, Armando Vera, Antonio Abbate and Elisabeth Weiss

    Citation: Cardio-Oncology 2020 6:6

    Content type: Research

    Published on:

  9. Anthracyclines are a mainstay of chemotherapy. However, a relatively frequent adverse outcome of anthracycline treatment is cardiomyopathy. Multiple genetic studies have begun to dissect the complex genetics u...

    Authors: Timothy N. McOwan, Lauren A. Craig, Anne Tripdayonis, Kathy Karavendzas, Michael M. Cheung, Enzo R. Porrello, Rachel Conyers and David A. Elliott

    Citation: Cardio-Oncology 2020 6:5

    Content type: Research

    Published on:

  10. High dose melphalan is commonly used as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. There are reports of adverse cardiac events with melphalan manifested by supraventri...

    Authors: Liang-Liang Ma, Ying Liu, Si-Xun Jia, Hai-Chen Lv, Mei-Yun Fang and Yun-Long Xia

    Citation: Cardio-Oncology 2020 6:4

    Content type: Short communication

    Published on:

  11. Irradiation of the heart during cancer radiotherapy is associated with a dose-dependent risk of heart failure. Animal studies have demonstrated that irradiation leads to an inflammatory response within the hea...

    Authors: Justin M. Canada, Georgia K. Thomas, Cory R. Trankle, Salvatore Carbone, Hayley Billingsley, Benjamin W. Van Tassell, Ronald K. Evans, Ryan Garten, Elisabeth Weiss and Antonio Abbate

    Citation: Cardio-Oncology 2020 6:2

    Content type: Short communication

    Published on:

  12. Our recent study has revealed that many hospitalized patients with acquired long QT syndrome (ALQTS) are cancer patients. This study aims to determine the risk factors and outcomes of hospitalized cancer patie...

    Authors: Yajuan Lin, Haixu Yu, Fei Liu, Cheng Chen, Yanli Zhang, Binhao Wang, Yiheng Yang, Ying Liu, Li Zhang and Yunlong Xia

    Citation: Cardio-Oncology 2020 6:3

    Content type: Research

    Published on:

  13. Continuous infusion of doxorubicin or dexrazoxane pre-treatment prior to bolus doxorubicin are proven strategies to protect against doxorubicin-induced cardiotoxicity. Recently, global longitudinal peak systol...

    Authors: Jieli Li, Hui-Ming Chang, Jose Banchs, Dejka M. Araujo, Saamir A. Hassan, Elizabeth A. Wagar, Edward T. H. Yeh and Qing H. Meng

    Citation: Cardio-Oncology 2020 6:1

    Content type: Research

    Published on:

  14. The lack of a validated symptom assessment instrument in Spanish for patients with cancer and heart failure (HF) can affect the care and impede the recruitment and participation of Spanish-speaking patients in...

    Authors: Anecita Fadol, Joaquin Buitrago, Maria C. Diaz, Valerie Shelton, Carolyn Harty and Tito R. Mendoza

    Citation: Cardio-Oncology 2019 5:19

    Content type: Research

    Published on:

  15. Cancer diagnostics and therapies have improved steadily over the last few decades, markedly increasing life expectancy for patients at all ages. However, conventional and newer anti-neoplastic therapies can ca...

    Authors: Neha Bansal, M. Jacob Adams, Sarju Ganatra, Steven D. Colan, Sanjeev Aggarwal, Rudolf Steiner, Shahnawaz Amdani, Emma R. Lipshultz and Steven E. Lipshultz

    Citation: Cardio-Oncology 2019 5:18

    Content type: Review

    Published on:

  16. Takotsubo syndrome (TTS), primarily an acute myocardial inflammatory condition engendered by catecholamine exposure, is associated with similar long-term mortality rates to those of patients with acute myocard...

    Authors: Thanh H. Nguyen, Jeanette Stansborough, Gao J. Ong, Sven Surikow, Timothy J. Price and John D. Horowitz

    Citation: Cardio-Oncology 2019 5:20

    Content type: Research

    Published on:

  17. Assessment of cardiac function after treatment for breast cancer relies on interval evaluation of ventricular function through echocardiography. Women who undergo mastectomy more frequently choose to undergo b...

    Authors: Joaquin Duarte Ow, Mohamad Hemu, Anel Yakupovich, Parva Bhatt, Hannah Gaddam, Nicole Prabhu, Ibtihaj Fughhi, Melody Cobleigh, Melissa Tracy, Louis Fogg and Tochukwu Okwuosa

    Citation: Cardio-Oncology 2019 5:17

    Content type: Research

    Published on:

  18. Dexrazoxane protects from lower-cumulative-dose doxorubicin cardiotoxicity, but the effect of dexrazoxane in children with sarcoma treated with higher-cumulative-dose doxorubicin is unknown.

    Authors: Lisa M. Kopp, Richard B. Womer, Cindy L. Schwartz, David H. Ebb, Vivian I. Franco, David Hall, Donald A. Barkauskas, Mark D. Krailo, Holcombe E. Grier, Paul A. Meyers, Leonard H. Wexler, Neyssa M. Marina, Katherine A. Janeway, Richard Gorlick, Mark L. Bernstein and Steven E. Lipshultz

    Citation: Cardio-Oncology 2019 5:15

    Content type: Research

    Published on:

  19. To enhance the understanding of cardiovascular care delivery in childhood cancer patients and survivors.

    Authors: Thomas D. Ryan, William L. Border, Carissa Baker-Smith, Ana Barac, Matthew J. Bock, Mary M. Canobbio, Nadine F. Choueiter, Devyani Chowdhury, Katheryn E. Gambetta, Julie S. Glickstein, Lavanya Kondapalli, Seema Mital, Vasum Peiris, Russell J. Schiff, Robert L. Spicer, Jeffrey A. Towbin…

    Citation: Cardio-Oncology 2019 5:16

    Content type: Research

    Published on:

  20. 5-Fluorouracil (5-FU) is an antimetabolite chemotherapy used for a variety of solid tumors. It has the potential to cause a wide spectrum of cardiotoxicity, ranging from asymptomatic electrocardiographic chang...

    Authors: Cai Yuan, Hiral Parekh, Carmen Allegra, Thomas J. George and Jason S. Starr

    Citation: Cardio-Oncology 2019 5:13

    Content type: Review

    Published on:

  21. Cardio-oncology is a young sub-specialty that addresses the needs of cancer patients at risk of, or who have experienced cancer therapy related cardiac dysfunction (CTRCD). This study assessed clinicians’ unde...

    Authors: J. Peng, M. Rushton, C. Johnson, C. Brezden-Masley, J. Sulpher, Miliyun G. Chiu, I. D. Graham and S. Dent

    Citation: Cardio-Oncology 2019 5:12

    Content type: Research

    Published on:

  22. Cardiotoxicity is a potential complication of anticancer therapy. While guidelines have been developed to assist practitioners, an effective, evidence based clinical pathway for the treatment of cardiotoxicity...

    Authors: Robyn A. Clark, Tania S. Marin, Alexandra L. McCarthy, Julie Bradley, Suchi Grover, Robyn Peters, Christos S. Karapetis, John J. Atherton and Bogda Koczwara

    Citation: Cardio-Oncology 2019 5:14

    Content type: Research

    Published on:

  23. Cardiovascular disease (CVD) is the leading non-malignant cause of death in childhood cancer survivors. Heightened risk of CVD is often attributable to treatment with anthracycline chemotherapy. Anthracycline-...

    Authors: Treya M. Long, Channa E. Marsh, Lawrence G. Dembo, Philip Watson, Karen E. Wallman, Thomas S. Walwyn, Catherine S. Choong and Louise H. Naylor

    Citation: Cardio-Oncology 2019 5:11

    Content type: Research

    Published on:

  24. Early recognition of anthracycline-induced cardiomyopathy may reduce morbidity and mortality in children, but risk stratification tools are lacking. This study evaluates whether electrocardiogram (ECG) changes...

    Authors: Lajja Desai, Lauren Balmert, Jennifer Reichek, Amanda Hauck, Katheryn Gambetta and Gregory Webster

    Citation: Cardio-Oncology 2019 5:10

    Content type: Research

    Published on:

  25. Improved cancer survival in patients treated with thoracic ionizing radiation (XRT) has resulted in unanticipated surge of aortic stenosis. Transcatheter aortic valve replacement (TAVR) has revolutionized the ...

    Authors: Nikhil Agrawal, Sharma Kattel, Sameer Waheed, Ankita Kapoor, Vasvi Singh, Ashutosh Sharma, Brian J. Page, Kristopher M. Attwood, Vijay Iyer, Saraswati Pokharel and Umesh C. Sharma

    Citation: Cardio-Oncology 2019 5:8

    Content type: Research

    Published on:

  26. Cardiotoxicity is an adverse effect of trastuzumab (TRA) in the treatment of human epidermal growth factor 2 positive (HER2+) breast cancer. Current literature on the cardioprotective effects of agents targete...

    Authors: Melissa Y. Y. Moey, Darla K. Liles and Blase A. Carabello

    Citation: Cardio-Oncology 2019 5:9

    Content type: Research

    Published on:

  27. Cancer is a chronic condition that induces significant emotional and physical stress, which may increase the risk for developing Takotsubo cardiomyopathy (TCM).

    Authors: Aakash Desai, Arish Noor, Saurabh Joshi and Agnes S. Kim

    Citation: Cardio-Oncology 2019 5:7

    Content type: Review

    Published on:

  28. The management of patients with cancer and concurrent heart failure (HF) is challenging. The increased complexity of treatment and the occurrence of multiple overlapping symptoms may lead to frequent hospital ...

    Authors: Anecita Fadol, Joylynmae Estrella, Valerie Shelton, Maryam Zaghian, Diane Vanbenschop, Valerie Counts, Tito R. Mendoza, David Rubio and Patricia A. Johnston

    Citation: Cardio-Oncology 2019 5:5

    Content type: Short communication

    Published on:

  29. Early identification of cardiac dysfunction by non-invasive imaging in HER2-positive breast cancer patients treated with trastuzumab is challenging. In particular multigated acquisition (MUGA) scan, which is m...

    Authors: Nathalie I. Bouwer, Crista Liesting, Marcel J. M. Kofflard, Sylvia M. Sprangers-van Campen, Jasper J. Brugts, Jos J. E. M. Kitzen, Michael A. Fouraux, Mark-David Levin and Eric Boersma

    Citation: Cardio-Oncology 2019 5:4

    Content type: Research

    Published on:

  30. Cancer survivors experience on average a 20% reduction in peak exercise capacity (VO2 peak) post-cancer treatment. Intermuscular fat (IMF) is a strong predictor of reduced exercise capacity in heart failure (HF) ...

    Authors: Kerryn W. Reding, Peter Brubaker, Ralph D’Agostino Jr, Dalane W. Kitzman, Barbara Nicklas, Dale Langford, Michael Grodesky and W. Gregory Hundley

    Citation: Cardio-Oncology 2019 5:3

    Content type: Short communication

    Published on:

  31. Anthracycline chemotherapy is an effective and widely used treatment for solid tumors and hematological malignancies regardless of its known cardiotoxicity. The mechanisms of the cardiotoxicity are not fully u...

    Authors: Amanda J. Favreau-Lessard, Hagen Blaszyk, Michael A. Jones, Douglas B. Sawyer and Ilka M. Pinz

    Citation: Cardio-Oncology 2019 5:2

    Content type: Research

    Published on:

  32. Cardiotoxicity associated with anthracycline-based chemotherapies has limited their use in patients with preexisting cardiomyopathy or heart failure. Dexrazoxane protects against the cardiotoxic effects of ant...

    Authors: Sarju Ganatra, Anju Nohria, Sachin Shah, John D. Groarke, Ajay Sharma, David Venesy, Richard Patten, Krishna Gunturu, Corrine Zarwan, Tomas G. Neilan, Ana Barac, Salim S. Hayek, Sourbha Dani, Shantanu Solanki, Syed Saad Mahmood and Steven E. Lipshultz

    Citation: Cardio-Oncology 2019 5:1

    Content type: Research

    Published on:

  33. Emerging evidence suggests potential arterial damage with the use of anthracycline-based chemotherapeutic regimens. We determined arterial function at rest and during exercise in anthracycline-treated adult su...

    Authors: Vivian Wing-yi Li, Anthony Pak-yin Liu, Karin Kar-Huen Ho, Jeffrey Ping-Wa Yau, Daniel Ka-leung Cheuk and Yiu-fai Cheung

    Citation: Cardio-Oncology 2018 4:9

    Content type: Research

    Published on:

  34. Cancer survivors treated with thoracic ionizing radiation are at higher risk of premature death due to myocardial ischemia. No therapy is currently available to prevent or mitigate these effects. We tested the...

    Authors: Umesh C. Sharma, Swati D. Sonkawade, Andrew Baird, Min Chen, Shirley Xu, Sandra Sexton, Anurag K. Singh, Adrienne Groman, Steven G. Turowski, Joseph A. Spernyak, Supriya D. Mahajan and Saraswati Pokharel

    Citation: Cardio-Oncology 2018 4:8

    Content type: Research

    Published on:

  35. Cardiotoxic effects of anthracycline therapy are a major cause of morbidity for childhood cancer survivors. The aim of this retrospective evaluation is to assess the efficacy of Tissue Doppler Imaging in the e...

    Authors: Francesco Venturelli, Riccardo Masetti, Marianna Fabi, Roberto Rondelli, Anna Martoni, Arcangelo Prete, Marco Bonvicini and Andrea Pession

    Citation: Cardio-Oncology 2018 4:6

    Content type: Research

    Published on:

  36. Doxorubicin chemotherapy is used across a range of adult and pediatric malignancies. Cardiac toxicity is common, and dysfunction develops over time in many patients. Biomarkers used for predicting late cardiac...

    Authors: Andrew Poklepovic, Yuesheng Qu, Molly Dickinson, Michael C. Kontos, Maciej Kmieciak, Elizabeth Schultz, Dipankar Bandopadhyay, Xiaoyan Deng and Rakesh C. Kukreja

    Citation: Cardio-Oncology 2018 4:7

    Content type: Research

    Published on:

  37. Anthracycline induced cardiomyopathy is a major cause of mortality and morbidity among pediatric cancer survivors. It has been postulated that oxidative stress induction and inflammation may play a role in the...

    Authors: Olga H. Toro-Salazar, Ji Hyun Lee, Kia N. Zellars, Paige E. Perreault, Kathryn C. Mason, Zhu Wang, Kan N. Hor, Eileen Gillan, Caroline J. Zeiss, Daniel M. Gatti, Brooke T. Davey, Shelby Kutty, Bruce T. Liang and Francis G. Spinale

    Citation: Cardio-Oncology 2018 4:4

    Content type: Research

    Published on:

  38. Approximately 2–3% of patients undergoing advanced heart failure therapies such as left ventricular assist devices (LVAD) and orthotropic heart transplantation (OHT) have chemotherapy-related cardiomyopathy, a...

    Authors: Raquel Araujo-Gutierrez, Sergio H. Ibarra-Cortez, Jerry D. Estep, Arvind Bhimaraj, Ashrith Guha, Imad Hussain, Myung H. Park, Guillermo Torre-Amione and Barry H. Trachtenberg

    Citation: Cardio-Oncology 2018 4:3

    Content type: Research

    Published on:

  39. Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed mu...

    Authors: Eric H. Yang, Cynthia Courtney, Vinisha Garg, Michael G. Fradley and Gary J. Schiller

    Citation: Cardio-Oncology 2018 4:2

    Content type: Short Communication

    Published on:

  40. Studies of cancer survivors treated with older radiotherapy (RT) techniques (pre-1990s) strongly suggest that ionizing radiation to the chest increases the risk of coronary heart disease (CHD). Our goal was to...

    Authors: Michael Jacob Adams, Susan G. Fisher, Steven E. Lipshultz, Roy E. Shore, Louis S. Constine, Marilyn Stovall, Ann Dozier, Kelly Thevenet-Morrison, Robert Block, Ronald G. Schwartz and Thomas A. Pearson

    Citation: Cardio-Oncology 2018 4:1

    Content type: Research

    Published on:

  41. Patients with cancer treatment-related cardiotoxicity, which may manifest as heart failure (HF), can present with dyspnea. Nurses frequently assess, triage and offer self-care strategies to patients experienci...

    Authors: F. Kelly, S. L. Carroll, M. Carley, S. Dent, R. Shorr, J. Hu, R. Morash and D. Stacey

    Citation: Cardio-Oncology 2017 3:7

    Content type: Research

    Published on:

  42. Cardiotoxicity from anticancer therapy affects heart function and structure. Cardiotoxicity can also lead to accelerated development of chronic diseases, especially in the presence of risk factors.

    Authors: Robyn A. Clark, Tania S. Marin, Narelle M. Berry, John J. Atherton, Jonathon W. Foote and Bogda Koczwara

    Citation: Cardio-Oncology 2017 3:6

    Content type: Research

    Published on:

  43. Antineoplastic therapy with the tyrosine kinase inhibitor pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC) has been associated with hypertension (HTN), cardiomyopathy, and cardiac dys...

    Authors: Daniel Pinkhas, Thai Ho and Sakima Smith

    Citation: Cardio-Oncology 2017 3:5

    Content type: Research

    Published on:

  44. Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. Howe...

    Authors: John H. Chen, Daniel J. Lenihan, Sharon E. Phillips, Shelton L. Harrell and Robert F. Cornell

    Citation: Cardio-Oncology 2017 3:4

    Content type: Research

    Published on:

  45. Atrial fibrillation (AF) is frequently observed in patients being treated for cancer and can lead to increased morbidity and mortality in this population. With the use of newer, targeted cancer therapies, seve...

    Authors: Aarti Asnani, Anastasia Manning, Moussa Mansour, Jeremy Ruskin, Ephraim P. Hochberg and Leon M. Ptaszek

    Citation: Cardio-Oncology 2017 3:2

    Content type: Review

    Published on:

  46. Sinus bradycardia is frequently observed in patients treated with crizotinib, a receptor tyrosine kinase inhibitor used for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung canc...

    Authors: Zhushan Zhang, Tai-Qin Huang, Igor Nepliouev, Hengtao Zhang, Adam S. Barnett, Paul B. Rosenberg, Sai-Hong I. Ou and Jonathan A. Stiber

    Citation: Cardio-Oncology 2017 3:1

    Content type: Research

    Published on:

Annual Journal Metrics

  • Speed
    36 days to first decision for reviewed manuscripts only
    36 days to first decision for all manuscripts
    87 days from submission to acceptance
    30 days from acceptance to publication

    Usage 
    61,438 Downloads
    214 Altmetric Mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here